A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting
Immunity, Inflammation and Disease · 2023
DOI: 10.1002/iid3.1063 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Immunity, Inflammation and Disease, 2023. Verfasst von Nazila Ghoreishi Amin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Keck School of Medicine, University of Southern California (USC), Los Angeles, California, USA. Hauptthemen laut MEDLINE: Biological Products, COVID-19, Psoriasis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
This systematic review and meta‐analysis aims to investigate the mutual impact of COVID‐19 and psoriasis to inform clinical practice and future research.
Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta‐analysis protocol for systematic reviews and searched PubMed, Web of Science, Scopus, and Google Scholar until May 1, 2022. Eligibility criteria included full‐text articles in English reporting COVID‐19 treatment outcomes in psoriasis patients. Studies on animals, letters to editors, non‐English studies, and studies with no access to full articles were excluded. Search results were screened and data were extracted by two groups of reviewers with any discrepancies resolved by the senior author. The risk of bias was assessed using ROBINS‐I for nonrandomized studies. The hospitalization rate, Intensive Care Unit (ICU) admission rate, case fatality rate, odds ratios of COVID‐19 infection and hospitalization rate in psoriasis patients were extracted and analyzed using random effects analysis to calculate pooled prevalence and odds ratios, as well as to explore heterogeneity.
Results
We found 1980 records from four databases and included 20 studies after screening and removing duplicates. These studies evaluated 185,000 psoriasis patients and included eight retrospective cohort studies, one case‐control study, three cross‐sectional studies, and eight case series studies. The impact of the COVID‐19 pandemic on psoriasis treatment and the outcome of COVID‐19 infection in psoriasis patients receiving different forms of treatment were evaluated. The pooled data from included studies showed that the incidence rate of COVID‐19 infection among psoriasis patients was 0.03% (confidence interval [CI]: 0.01–0.06), with a pooled odds ratio of 1.97 (CI: 0.69–5.60) compared to the general population. The hospitalization rate, ICU admission rate, and case fatality rate for psoriasis patients with COVID‐19 were 0.17 (CI: 0.10–0.31), 0.06 (CI: 0.06–0.46), and 0.02 (CI: 0.01–0.04), respectively. Additionally, psoriasis patients receiving systemic nonbiologic therapy had a pooled odds ratio of 2.32 (CI: 1.18–4.57) for hospitalization compared to those using biologic agents.
Conclusion
Studies have shown that biologic therapy for psoriasis did not increase the risk of hospitalization due to COVID‐19 infection and may have even offered some protection. Treatment adherence was higher in psoriasis patients receiving biologic therapies than those receiving conventional therapies. These findings suggest that psoriasis treatment did not negatively impact COVID‐19 infection and that treatment could be continued on a case‐by‐case basis during the pandemic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Keck School of Medicine, University of Southern California (USC), Los Angeles, California, USA.
- Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), Iran University of Medical Sciences, Tehran, Iran.
- Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
- School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Sepehr Khosravi, Najmolsadat Atefi, Farnoosh Seirafianpour, Sahand Farhoodi
Zitieren
APA
Ghoreishi Amin, N., Khosravi, S., Atefi, N., Seirafianpour, F., Farhoodi, S., & Goodarzi, A. (2023). A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1063
Vancouver
Ghoreishi Amin N, Khosravi S, Atefi N, Seirafianpour F, Farhoodi S, Goodarzi A. A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting. Immunity, Inflammation and Disease. 2023. doi:10.1002/iid3.1063
BibTeX
@article{GhoreishiAmin2023,
author = {Ghoreishi Amin, Nazila and Khosravi, Sepehr and Atefi, Najmolsadat and Seirafianpour, Farnoosh and Farhoodi, Sahand and Goodarzi, Azadeh},
title = {A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting},
journal = {Immunity, Inflammation and Disease},
year = {2023},
doi = {10.1002/iid3.1063}
}
EUVIMED